Dr. Evan Jacob Lipson, MD

Dr. Lipson practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Lipson's NPI, 1376697094, was assigned on January 22, 2007. Dr. Lipson graduated from Icahn School of Medicine at Mount Sinai in 2005. Dr. Lipson holds Maryland license D67921.

Dr. Lipson's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Lipson's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Lipson is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Lipson to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lipson practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Lipson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Lipson is licensed in Maryland.

CMS data shows 742 Medicare services from Dr. Lipson across 5 procedure codes in 2024, for 297 Medicare patients. Medicare paid $53,499 for them.

CMS counts 297 Medicare patients who saw Dr. Lipson in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lipson's median patient age at 76, with 41% women.

In 2024, Dr. Lipson wrote 81 Medicare Part D claims for 27 patients. 68% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $28,552 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Lipson for performance year 2024, reported as part of a group. CMS lists Dr. Lipson as offering telehealth.

Dmand AI links 111 papers to Dr. Lipson, published from 2010 to 2025. 2025 was the busiest year, with 10. The most frequent topics are Melanoma, Skin Neoplasms and Immune Checkpoint Inhibitors. Dr. Lipson has published most often in J Immunother Cancer. Dr. Lipson's most frequent co-authors are William Sharfman, MD, Suzanne Louise Topalian, MD and Jarushka Naidoo, BAO, BCH, MB.

Dmand AI links Dr. Lipson to 4 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Merkel Cell, Melanoma and Polyomavirus Infections. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 241 general payments to Dr. Lipson from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 84% of the total. Bristol-Myers Squibb Company paid the most, $55,102. It also lists 23 research payments totaling $4,869 from 2019 to 2025.

Dr. Lipson graduated from Icahn School of Medicine at Mount Sinai in 2005.